Click here for The Motley Fool's resources on Coronavirus and the market.

Shannon Jones

Shannon Jones

TMFLilDebbie

Recent articles

cover_IF

3 Biotech Companies Analyzed

We examine three biotech companies' past performances and future outlooks.


cover_IF

Like Vanguard for Healthcare Costs: An Interview With HealthEquity CEO John Kessler

HealthEquity's CEO explains how the company makes money while helping people tackle healthcare savings.


cover_IF

Hot Takes on 6 Hot IPOs

The Industry Focus team weighs in on some of the biggest IPOs and hottest news of the last year.


cover_IF

Bearish Signs and Antitrust Tensions

The Industry Focus hosts gather round the table to talk about (potentially) impending (short-term) doom for the market and big tech.


cover_IF

The Fastest-Growing Healthcare Company You've Never Heard Of

This medical device maker is growing rapidly and has already treated its investors to huge gains. Here's why Wall Street is so excited about where this company is heading.

GettyImages-923244300

2018 ASCO Conference Roundup

All your Motley Fool coverage of the 2018 ASCO Conference in one place.


IF_healthcare

A Promising Step for Medical Marijuana

Medical marijuana enthusiasts, get hyped -- GW Pharma’s advisory committee meeting results could mean huge things for the industry.


IF_healthcare

Why One Drug Flop Tanked Incyte's Stock

Biotech is risky business, and Incyte shareholders have not had a good week after a key drug flopped its phase 3.


drugs-money_large

These 3 Biotechs Just Crushed Analyst Expectations

But before you invest in any of them, you should read this.


Scientists

3 Key Things Every CAR-T Investor Should Watch

The first CAR-T therapy recently won a unanimous thumbs up for approval. But that doesn't mean CAR-T stocks are out of the woods just yet.

3 Ways This $30 Billion Market Is Bristol's for the Taking

How this "Big Pharma" is revolutionizing the fight against cancer and well-positioned for long-term growth.


3 Key Pipeline Developments for Gilead Investors to Watch

Forget Hepatitis C -- here are 3 key developments investors should keep on their radars in 2016.